Table 2 Demographic characteristics of all participants

Age (years) (mean ± SD)¹

35.46 ± 12.72

35.32 ± 11.77

0.9

Gender²

Male 2 (6.67%)

Male 51 (71.83%)

 < 0.01

Female 28 (93.33%)

Female 20 (28.17%)

Disease duration (years) (mean ± SD)¹

–

4.67 ± 4.38

–

Family history (Yes/No)²

–

8/63

–

Mouth ulcers²

–

64 (90.14%)

–

Genital ulcers²

–

53 (74.65%)

–

Erythema nodosum²

–

6 (8.45%)

–

Pustules²

–

18 (25.35%)

–

Arthralgia²

–

19 (26.76%)

–

Arthritis²

–

10 (14.08%)

–

Major vascular lesions²

–

18 (25.35%)

–

CNS complications²

–

6 (8.45%)

–

Ocular problems²

–

53 (74.65%)

–

GIT illness²

–

6 (8.45%)

–

Pulmonary diseases²

–

3 (4.23%)

–

Fever²

–

3 (4.23%)

–

Headache²

–

6 (8.45%)

–

Treatment status²

–

 Steroid dose (mg)

–

9.72 ± 10.45

 Steroid (Prednison or Solumedrol IV)

–

58 (81.69%)

 Colchicines

–

50 (70.42%)

 Anticoagualtion (Warfarin or Marivan)

–

6 (8.45%)

 Azathioprine

–

35 (49.3%)

 Cyclophosphamide (Endoxan)

–

12 (16.9%)

 Cyclosporin

–

2 (2.82%)

 Biological treatment (Rituximab and Etanercept)

–

2 (2.82%)